Physician profile
Brandon Lee Locklear
NPI 1386336394
$653.22
in general payments reported to CMS, 2019-2025
16 companies · $45.09 in 2025
The $45.09 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.53 · 2024: $514 · 2025: $45.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $170.44 | 2024 | Watchman Flx |
| Irhythm Technologies, INC. | $113.28 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $53.58 | 2023-2024 | |
| Baxter Healthcare | $45.09 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $44.94 | 2023-2024 | Verquvo |
| Medtronic, INC. | $27.70 | 2023-2024 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $24.54 | 2024 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $23.85 | 2024 | Jardiance |
| Celgene Corporation | $23.63 | 2024 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.20 | 2024 | Lifevest |
| Novo Nordisk INC | $20.80 | 2024 | Ozempic |
| Scpharmaceuticals INC. | $20.02 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $18.93 | 2023 | Opsumit |
| Astrazeneca Pharmaceuticals Lp | $17.66 | 2024 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2024 | Camzyos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.